A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients

BACKGROUND: Hematopoietic-cell transplant (HCT) recipients are at risk for severe respiratory syncytial virus (RSV) infection. We evaluated the RSV fusion inhibitor presatovir in a randomized, double-blind, Phase II trial in HCT recipients with RSV upper respiratory tract infections. METHODS: Patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Chemaly, Roy F, Dadwal, Sanjeet S, Bergeron, Anne, Ljungman, Per, Kim, Yae-Jean, Cheng, Guang-Shing, Pipavath, Sudhakar N, Limaye, Ajit P, Blanchard, Elodie, Winston, Drew J, Stiff, Patrick J, Zuckerman, Tsila, Lachance, Silvy, Rahav, Galia, Small, Catherine B, Mullane, Kathleen M, Patron, Roberto L, Lee, Dong-Gun, Hirsch, Hans H, Waghmare, Alpana, McKevitt, Matt, Jordan, Robert, Guo, Ying, German, Polina, Porter, Danielle P, Gossage, David L, Watkins, Timothy R, Marty, Francisco M, Chien, Jason W, Boeckh, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108134/
https://www.ncbi.nlm.nih.gov/pubmed/31793991
http://dx.doi.org/10.1093/cid/ciz1166

Ejemplares similares

Ejemplares similares